Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression
暂无分享,去创建一个
John H Krystal | Tung-Ping Su | Ya-Mei Bai | Pei-Chi Tu | Ralitza Gueorguieva | Cheng-Ta Li | P. Tu | T. Su | J. Krystal | R. Gueorguieva | C. Hong | Ya-Mei Bai | Mu-Hong Chen | Chen-Jee Hong | Mu-Hong Chen | Cheng-Ta Li | Wei-Chen Lin | Wei-Chen Lin | Chih-Ming Cheng | Chih-Ming Cheng
[1] Se-Won Lim,et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder , 2006, Brain Research.
[2] Husseini Manji,et al. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study , 2016, Biological Psychiatry.
[3] D. Luckenbaugh,et al. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. , 2012, British journal of clinical pharmacology.
[4] G. Laje,et al. Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression , 2012, Biological Psychiatry.
[5] M. Fava,et al. What Did STAR✫D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression , 2012 .
[6] John H Krystal,et al. Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.
[7] Bang-Hung Yang,et al. The effects of low‐dose ketamine on the prefrontal cortex and amygdala in treatment‐resistant depression: A randomized controlled study , 2016, Human brain mapping.
[8] K. Hashimoto,et al. Association between brain‐derived neurotrophic factor 196 G/A polymorphism and personality traits in healthy subjects , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[9] F. McMahon,et al. Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients , 2012, Biological Psychiatry.
[10] J. Krystal,et al. Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond , 2013, Biological Psychiatry.
[11] I. Feinberg,et al. Stimulation of NREM Delta EEG by Ketamine Administration during Waking: Demonstration of Dose Dependence , 1995, Neuropsychopharmacology.
[12] Kangguang Lin,et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population. , 2012, Psychiatric genetics.
[13] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[14] C. Correll,et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study , 2015, Psychological Medicine.
[15] D. Kupfer,et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. , 2004, Controlled clinical trials.
[16] Harlan M. Krumholz,et al. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach , 2017, JAMA psychiatry.
[17] A. Maurset,et al. Interaction of the chiral forms of ketamine with opioid, phencyclidine, σ and muscarinic receptors , 1995 .
[18] Nick Glozier,et al. Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis , 2015, The international journal of neuropsychopharmacology.
[19] Blair T. Johnson,et al. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.
[20] A. Belger,et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. , 2005, Archives of general psychiatry.
[21] Xi-Ping Huang,et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites , 2016, Nature.
[22] I. Oye,et al. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. , 1995, Pharmacology & toxicology.
[23] Paresh D Patel,et al. Variant Brain-Derived Neurotrophic Factor (BDNF) (Met66) Alters the Intracellular Trafficking and Activity-Dependent Secretion of Wild-Type BDNF in Neurosecretory Cells and Cortical Neurons , 2004, The Journal of Neuroscience.
[24] D. Revicki,et al. Telephone assessment of depression severity. , 1993, Journal of psychiatric research.
[25] E. Ballard,et al. Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. , 2017, The Journal of clinical psychiatry.
[26] J. Overall,et al. The Brief Psychiatric Rating Scale , 1962 .
[27] K. Hagi,et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories , 2016, Psychological Medicine.
[28] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[29] Dennis S. Charney,et al. Ketamine for Depression: Where Do We Go from Here? , 2012, Biological Psychiatry.
[30] D. Sheehan,et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.
[31] G. Aghajanian,et al. Brain-Derived Neurotrophic Factor Val66Met Allele Impairs Basal and Ketamine-Stimulated Synaptogenesis in Prefrontal Cortex , 2012, Biological Psychiatry.
[32] D. Luckenbaugh,et al. An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. , 2016, Journal of affective disorders.
[33] I. Feinberg,et al. Ketamine Administration During Waking Increases Delta EEG Intensity in Rat Sleep , 1993, Neuropsychopharmacology.
[34] D. Luckenbaugh,et al. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. , 2017, Journal of affective disorders.